SCHEMBL5880193

SCHEMBL5880193

CS(=O)(=O)c1ccc(CC(=O)N/N=C/c2ccccc2OS(=O)(=O)c2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.49
KMT2A Q03164 5/20 0.49
MAPT P10636 5/20 0.49
MEN1 O00255 4/20 0.49
HTT P42858 3/20 0.49
NPC1 O15118 1/20 0.48
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
GAA P10253 1/20 0.44
MAPK1 P28482 1/20 0.43
ALDH1A1 P00352 5/20 0.42
RORC P51449 1/20 0.41
CYP2D6 P10635 1/20 0.41
KDM4E B2RXH2 1/20 0.41
FAAH O00519 1/20 0.40
MGLL Q99685 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5880196 1.00 LMNA (0.49) LMNAKMT2AMAPTMEN1HTT
SCHEMBL5879910 0.95 LMNA (0.51) LMNAKMT2AMAPTMEN1HTT
SCHEMBL5879907 0.95 LMNA (0.51) LMNAKMT2AMAPTMEN1HTT
SCHEMBL5880033 0.93 LMNA (0.48) LMNAKMT2AMAPTMEN1HTT
SCHEMBL5880038 0.93 LMNA (0.48) LMNAKMT2AMAPTMEN1HTT
SCHEMBL5880090 0.92 MEN1 (0.54) LMNAKMT2AMAPTMEN1HTT
SCHEMBL5880094 0.92 MEN1 (0.54) LMNAKMT2AMAPTMEN1HTT
SCHEMBL5879902 0.91 KMT2A (0.52) LMNAKMT2AMAPTMEN1HTT
SCHEMBL5879904 0.91 KMT2A (0.52) LMNAKMT2AMAPTMEN1HTT
SCHEMBL5880151 0.91 LMNA (0.47) LMNAKMT2AMAPTMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7026339-B2 Inhibitors of HCV NS5B polymerase PFIZER INC. 2006-04-11 US disclosed
US-20050154056-A1 [(hetero)aryl or cycloalkylacetylhydrazono]methylbenzene derivatives, o-substituted with (hetero)aryl- or cycloalkyl- sulfonyloxy-, sulfonylamino-, S(O)0-2methyl-, or methoxy- groups, e.g., 3-chloro-2-((E)-{[(3-methoxyphenyl)acetyl]hydrazono}methyl)phenyl 4-(trifluoromethyl)benzenesulfonate PHARMACIA & UPJOHN COMPANY 2005-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154056-A1 [(hetero)aryl or cycloalkylacetylhydrazono]methylbenzene derivatives, o-substituted with (hetero)aryl- or cycloalkyl- sulfonyloxy-, sulfonylamino-, S(O)0-2methyl-, or methoxy- groups, e.g., 3-chloro-2-((E)-{[(3-methoxyphenyl)acetyl]hydrazono}methyl)phenyl 4-(trifluoromethyl)benzenesulfonate ACACB, HCCS, HAVCR2 LMNA 4281/4885KMT2A 1234/4885MAPT 4629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.